

## Agila gets FDA nod for Zoledronic Acid Injection

06 March 2013 | News | By BioSpectrum Bureau



**Bangalore:** Agila Specialties, a wholly owned subsidiary of Strides Arcolab, has received ANDA approval for Zoledronic Acid Injection 4 mg (base) / 5 mL, packaged in single dose vials.

According to IMS data, the US market for Zoledronic Acid 5ML s approximately \$520 Million. The product is expected to be launched shortly.

Zoledronic Acid is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer. Zoledronic acid is also used with cancer chemotherapy to treat bone problems that may occur with multiple myeloma and other types of cancer (such as breast, lung) that have spread to the bones.